Literature DB >> 17103384

Studies on the metabolism and toxicological detection of the designer drug 2,5-dimethoxy-4-methyl-beta- phenethylamine (2C-D) in rat urine using gas chromatographic/mass spectrometric techniques.

Denis S Theobald1, Hans H Maurer.   

Abstract

The phenethylamine-derived designer drug 2,5-dimethoxy-4-methyl-beta-phenethylamine (2C-D) was found to be metabolized in rats by O-demethylation at position 2 or 5 followed by N-acetylation or by deamination with oxidation to the corresponding acids or reduction to the corresponding alcohol. Furthermore, 2C-D was hydroxylated at the methyl group or deaminated followed by reduction to the corresponding alcohol or by oxidation to the corresponding acid. Most of the metabolites were excreted in conjugated form. The authors' systematic toxicological analysis (STA) procedure using full-scan GC/MS allowed the detection of an intake of a dose of 2C-D in rat urine that corresponds to a common drug user's dose. Assuming similar metabolism, the described STA procedure should be suitable for proof of an intake of 2C-D in human urine. Copyright 2006 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17103384     DOI: 10.1002/jms.1128

Source DB:  PubMed          Journal:  J Mass Spectrom        ISSN: 1076-5174            Impact factor:   1.982


  3 in total

Review 1.  Microwave-assisted derivatization procedures for gas chromatography/mass spectrometry analysis.

Authors:  Sandra L Söderholm; Markus Damm; C Oliver Kappe
Journal:  Mol Divers       Date:  2010-03-12       Impact factor: 2.943

2.  Correlating the metabolic stability of psychedelic 5-HT₂A agonists with anecdotal reports of human oral bioavailability.

Authors:  Sebastian Leth-Petersen; Christoffer Bundgaard; Martin Hansen; Martin A Carnerup; Jan Kehler; Jesper Langgaard Kristensen
Journal:  Neurochem Res       Date:  2014-02-12       Impact factor: 3.996

3.  Current literature in mass spectrometry.

Authors: 
Journal:  J Mass Spectrom       Date:  2007-01       Impact factor: 1.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.